A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral Neuropathy

NCT00455520 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

395

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Neuropathy

Interventions

DRUG: CG5503
DRUG: placebo

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborators

[object Object]